LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
LB Pharmaceuticals (LBRX) had its price target raised by Stifel Nicolaus from $35.00 to $40.00. They now have a "buy" rating on the stock.
LB Pharmaceuticals Inc GAAP EPS of -$0.45 [Seeking Alpha]
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia